

ASX Announcement

Race appoints Professor Michael Kelso as Principal Scientist

- Professor of Medicinal Chemistry at the School of Chemistry and Molecular Bioscience at the University of Wollongong
- Professor Kelso brings over 25 years experience in oncology, medicinal chemistry, drug development and formulation
- Appointment follows an intensive four-month recruitment process to find a Principal Scientist of appropriate calibre and experience

20 May 2021 – Race Oncology Limited (“Race”) is pleased to announce the appointment of Professor Michael Kelso as Principal Scientist. Prof Kelso will be responsible for providing scientific leadership, developing, managing, and implementing Race’s preclinical and clinical research programs in collaboration with Race’s Chief Scientific Officer, Dr Daniel Tillett and Chief Medical Officer, Dr David Fuller.

An internationally experienced researcher, Prof Kelso brings a deep understanding of drug chemistry, formulation and development. His more than 25 years of R&D experience spans a wide range of areas in medicinal chemistry, including oncology, antimicrobial drug development and drug formulation. Prof Kelso has published 69 scientific research papers and 7 patents and has attracted 18 grants from the National Health and Medical Research Council (NH&MRC), Australian Research Council (ARC), and the US National Institutes of Health (NIH), as well as industry and charity foundations.

Prof Kelso will join Race Oncology on 12 July 2021 from University of Wollongong, where he was the Professor of Medicinal Chemistry. Prior to his appointment at the University of Wollongong, Prof Kelso was a NH&MRC CJ Martin Postdoctoral Research Fellow at the Department of Chemistry, The Scripps Research Institute, CA, USA.

Commenting on the new appointment, Race Oncology CSO Dr Daniel Tillett, *“This is an important appointment for Race as Michael brings significant scientific experience and capability. Michael has been a highly successful researcher and I look forward to working with him on the execution of our Three Pillar strategy and maximising the significant opportunities we have ahead for Bisantrene in the lab and clinic.”*

Prof Michael Kelso said, *“I’m thrilled to be joining the team at Race at such an exciting and pivotal time for the company. Capitalising on Bisantrene’s exquisite FTO inhibitory properties and delivering major clinical impacts across multiple cancer types is a powerful motivator for a career drug hunter like me.”*

Prof Kelso holds a Bachelor of Medicinal Chemistry (First Class Honours) from the University of Wollongong and a PhD from University of Queensland. He is a member of the Royal Australian Chemical Institute and the American Chemical Society.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Bisantrene.

Bisantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Bisantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. The Company also has compelling clinical data for the use of Bisantrene as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of Bisantrene.

See more at www.raceoncology.com.

Release authorised by:

Phil Lynch, CEO/MD on behalf
of the Race Board of Directors
phillip.lynch@raceoncology.com

Media contact:

Jane Lowe
+61 411 117 774
jane.lowe@irdepartment.com.au